SCHEMBL1330580

SCHEMBL1330580

C[C@@H]1C[C@H](C)C(=O)OC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GMNN O75496 1/20 0.36
PPM1B O75688 1/20 0.36
LMNA P02545 1/20 0.36
PPP1CC P36873 1/20 0.36
TFPI2 P48307 1/20 0.36
RAB9A P51151 1/20 0.36
PPP5C P53041 1/20 0.36
PPP1CA P62136 1/20 0.36
PMP22 Q01453 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TP53 P04637 1/20 0.36
CYP2D6 P10635 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36
CA1 P00915 2/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2168943 1.00 SMN1; SMN2 (0.36) SMN1; SMN2KDM4EGMNNPPM1BLMNA
SCHEMBL7310733 1.00 SMN1; SMN2 (0.36) SMN1; SMN2KDM4EGMNNPPM1BLMNA
SCHEMBL16003245 0.82 KDM4E (0.30) SMN1; SMN2KDM4EGMNNPPM1BLMNA
SCHEMBL18789034 0.78 POLB (0.36)
SCHEMBL16657577 0.76
SCHEMBL18588303 0.76
SCHEMBL2692834 0.76
SCHEMBL7085873 0.71 CA1 (0.32) SMN1; SMN2CA1CA2CA4KMT2A
SCHEMBL18427530 0.71 SMN1; SMN2 (0.44) SMN1; SMN2KDM4EGMNNPPM1BLMNA
SCHEMBL7282746 0.71 SMN1; SMN2 (0.33) SMN1; SMN2KDM4EGMNNPPM1BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 US disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 US disclosed
US-11535660-B1 Modulators of G-protein coupled receptors Cannot Therapeutics, Inc. (US) 2022-12-27 US disclosed
US-11535660-B1 Modulators of G-protein coupled receptors Cannot Therapeutics, Inc. (US) 2022-12-27 US disclosed
EP-3768294-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS Carmot Therapeutics, Inc. (US) 2021-01-27 EP disclosed
CN-112236161-A Modulators of G protein-coupled receptors 卡莫特治疗学股份有限公司 2021-01-15 CN disclosed
WO-2019183577-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. (US) 2019-09-26 WO disclosed
US-20110282075-A1 METHOD FOR PREPARING VITTATALACTONE ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) 2011-11-17 US disclosed
US-20110282075-A1 METHOD FOR PREPARING VITTATALACTONE ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) 2011-11-17 US disclosed
EP-0081817-B1 OPTICALLY-ACTIVE DIAMIDE DERIVATIVES Yamasa Shoyu Kabushiki Kaisha (JP) 1985-05-15 EP disclosed
US-4495355-A Optically-active diamide derivatives YAMASA SHOYU KABUSHIKI KAISHA (JP) 1985-01-22 US disclosed
US-4479963-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1984-10-30 US disclosed
EP-0105919-A1 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES. CIBA GEIGY AG (CH) 1984-04-25 EP disclosed
WO-1983003828-A1 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES CIBA-GEIGY AG (CH) 1983-11-10 WO disclosed
EP-0081817-A1 Optically-active diamide derivatives Yamasa Shoyu Kabushiki Kaisha (JP) 1983-06-22 EP disclosed
US-4374847-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1983-02-22 US disclosed
EP-0050850-A1 1-Carboxyalkanoylindolin-2-carboxylic acids and derivatives thereof, processes for their preparation, and pharmaceutical compositions containing these compounds CIBA-GEIGY AG (CH) 1982-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR SMN1; SMN2 2080/4885KDM4E 3433/4885GMNN 3401/4885
US-20110282075-A1 METHOD FOR PREPARING VITTATALACTONE FNTA, LCAT, AAAS SMN1; SMN2 4674/4885KDM4E 3569/4885GMNN 387/4885
US-11535660-B1 Modulators of G-protein coupled receptors GIPR, GLP1R, GCGR SMN1; SMN2 2241/4885KDM4E 3179/4885GMNN 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.